Sandoz International GmbH
Budget
€200 — €0
EP Access
1
accredited persons
Staff
2
0.75 FTE
EU Grants
None
Mission & Goals
Our Purpose at Sandoz is clear: pioneering access for patients. Our Purpose shines through in our rich heritage, as in our plans for the future. Our Vision is to be the world’s leading and most valued generics and biosimilars company. We aim to be valued for how we run our business, but also for the positive impact we have on society. That’s how we will deliver sustainably on our Purpose.
EU Legislative Interests
Antimicrobial Resistance, EU Pharmaceutical Legislation, EU Pharmaceutical Strategy, F-Gas Regulation, Industrial Strategy, IP Action Plan, Orphan Medicines Regulation, Pediatric Medicines, Pharmaceutical Pricing, Waste Water Treatment Directive, Critical Medicines Act, Biotech Act
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Medicines for Europe (including Biosimilar Medicines Sector Group and VAM Sector Group) European Healthcare Distribution Association (GIRP) APIC (CEFIC Sector Group) EPC (European Policy Center)
Additional Information
In 2024 we disclosed expenditures for only the last quarter, October-December 2023, as all costs until spin-off from Novartis were reported as part of Novartis entry to Transparency Register (Sandoz spun off on Oct 4, 2023). In 2025 we disclose full year 2024, hence the significant increase.
Commissioner Meetings
No recorded meetings with EU commissioners.